Deferasirox for managing iron overload in people with thalassaemia-Reference-Cited by-同舟云学术

Deferasirox for managing iron overload in people with thalassaemia

Published:2017-08-15 Issue:8 Volume:2017 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Bollig Claudia¹,Schell Lisa K²,Rücker Gerta³,Allert Roman⁴,Motschall Edith⁵,Niemeyer Charlotte M⁶,Bassler Dirk⁷,Meerpohl Joerg J¹

Affiliation:

1. Medical Center - Univ. of Freiburg, Faculty of Medicine, Univ. of Freiburg; Cochrane Germany; Breisacher Straße 153 Freiburg Germany 79110

2. Cologne Germany

3. Faculty of Medicine and Medical Center - University of Freiburg; Institute for Medical Biometry and Statistics; Stefan-Meier-Str. 26 Freiburg Germany 79104

4. University Hospital Frankfurt, Goethe University; Department of Obstetrics and Gynaecology; Frankfurt Germany

5. Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg; Center for Medical Biometry and Medical Informatics; Stefan-Meier-Str. 26 Freiburg Germany 79104

6. University Medical Center Freiburg; Pediatric Hematology & Oncology, Center for Pediatrics & Adolescent Medicine; Mathildenstrasse 1 Freiburg Germany 79106

7. University Hospital Zurich and University of Zurich; Department of Neonatology; Frauenklinikstrasse 10 Zurich Switzerland

Publisher

Wiley

Subject

Pharmacology (medical)

Reference219 articles.

1. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis;Angelucci;Blood,2005

2. Growth and development of paediatric patients with beta-thalassaemia treated with deferasirox for up to 5 years;Aydinok;Haematologica,2010

3. A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox;Aydinok;Haematologica,2010

4. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion-dependent anemia;Brissot;Blood,2005

5. Phase III evaluation of once-daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta-thalassemia and transfusional hemosiderosis;Cappellini;Blood,2004

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of the magnetic resonance 3D multiecho Dixon sequence for quantifying hepatic iron overload and steatosis in patients with thalassemia;Magnetic Resonance Imaging;2024-09

2. Rosmarinic acid plus deferasirox inhibits ferroptosis to alleviate crush syndrome-related AKI via Nrf2/Keap1 pathway;Phytomedicine;2024-07

3. Emerging regulatory mechanisms in cardiovascular disease: Ferroptosis;Biomedicine & Pharmacotherapy;2024-05

4. Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia;Cochrane Database of Systematic Reviews;2023-11-17

5. Therapeutic Approaches Targeting Ferroptosis in Cardiomyopathy;Cardiovascular Drugs and Therapy;2023-11-06